Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

Respiratory Distress Syndrome Clinical Trial

Official title:

Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05387278
• Other study ID #: EW-01
• Status: Recruiting
• Phase: Phase 1
• Start date: March 20, 2023
• Est. completion date: December 2023

Study information

• Verified date: October 2022
• Source: Vitti Labs, LLC
• Contact: Mukesh Kumar
• Phone: 2407504893
• Email: mkumar[@]fdamap.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes. The biggest medical challenge in the response to COVID-19 is ARDS requiring hospitalization in an intensive care setting and ventilator dependence. Intravenously administered umbilical cord derived exosomes and stem cells have been reported in literature to alleviate pulmonary distress in such patients. The purpose of this study is to explore the safety and benefits of intravenous administration of WJPure and EVPure in the treatment of COVID-19 patients with moderate to severe ARDS. .

Description:

One of the hallmark features of the progression of COVID-19 is lung injury from the viral infection leading to potentially acute respiratory distress syndrome (ARDS) and respiratory failure requiring ventilator support. In patients who survive ARDS, regardless of the pathology, there is evidence that their long-term quality of life is adversely affected. The rationale for the dose and dosing regimen proposed in this study is based on the safe administration and benefits of this treatment regimen reported to us last year by physicians trying to treat moderate to severe COVID-19 patients. In those reports, the intravenous route of administration was used. It has been reported that dosing every 2 days amplified the benefit of the combination of exosomes and mesenchymal stem cells. It has been suggested based on clinical experience that the exosomes and MSCs are complementary to one another as well as enhancing the innate abilities of both. During the early days of the pandemic, intravenous infusion of a mixture of EV-Pure™ and WJ-Pure™ was reported to benefit hospitalized patients with moderate to severe COVID-19 related ARDS. This study is designed to systematically explore the risk and benefits of intravenous infusion of EV-Pure™ and WJ-Pure™ in the treatment of hospitalized COVID-19 patients with moderate to severe ARDS. This is a proof of concept, double-blind, placebo-controlled trial to evaluate the safety and efficacy of intravenous infusion of EV-Pure™ and WJ-Pure™, versus placebo, for use in the treatment of moderate to severe ARDS related to COVID-19. This is an add-on treatment study; subjects will be allowed to take standard of care treatments available. The study will have two arms (n=10 each): 1. Experimental/treatment arm: EV-Pure™ and WJ-Pure™ plus standard care 2. Placebo: Cryopreservation media plus standard care The study duration would be 5 days of treatment plus 12 weeks follow up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 2023
• Est. primary completion date: October 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects will be eligible for enrollment in the study only if they meet the following

criteria:

1. Male or female, aged at 18 years (including) to 75 years old.

2. Patient with a confirmed SARS-CoV-2 infection (by positive reverse-transcription polymerase chain reaction (RT-PCR) from nasopharyngeal sample or any other sample)

3. Hospitalized with moderate to severe ARDS.

4. Have ARDS or acute lung injury, comply with any of the following:

i. Respiratory distress, Respiratory rate (RR) = 30 times/min ii. Pulse oxygen saturation (SpO2) at rest = 93% iii. Partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) = 300mmHg

5. If childbearing age: agree to practice effective birth control from screening until 12 weeks after the last study treatment.

Exclusion Criteria:

• Subjects will be ineligible for enrollment in the study if they meet any of the

following criteria:

1. Patient under invasive mechanical ventilation for more than 48 hours

2. Allergic or hypersensitive to any of the ingredients.

3. Pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other viruses.

4. Obstructive HABP/VABP induced by lung cancer or other known causes.

5. Carcinoid syndrome.

6. History of long-term use of immunosuppressive agents.

7. History of Class III or IV pulmonary arterial hypertension.

8. Patient with chronic respiratory disease under oxygen therapy.

9. Undergoing hemodialysis or peritoneal dialysis.

10. Estimated or actual rate of creatinine clearance < 15 mL/min.

11. History of moderate and severe liver disease (Child-Pugh score >12).

12. History of deep venous thrombosis or pulmonary embolism within the last 3 years.

13. Undergoing extracorporeal membrane oxygenation (ECMO) or high-frequency oscillatory ventilation support.

14. Patient included in another ongoing interventional therapeutic trial.

15. Pregnant or Lactating.

16. Any condition of unsuitable for the study determined by Principal Investigator (PI).

Related Conditions & MeSH terms

• Acute Lung Injury
• Coronavirus Infections
• COVID-19
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn
• Syndrome
• Virus Diseases

Intervention

Drug:
• EV-Pure™ and WJ-Pure™
The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care
• Placebo
Cryopreservation media plus standard care

Locations

Country	Name	City	State
United States	Kit Bartalos	Liberty	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Vitti Labs, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To Assess the safety of EV-Pure™ and WJ-Pure™ administration in patients exhibiting moderate to severe ARDS associated with COVID-19, compared to placebo.	Evaluate incidences of Treatment-Emergent Adverse Events following EV-Pure™ and WJ-Pure™ administeration in patients exhibiting moderate to severe ARDS associated with COVID-19 compared to placebo. Presence of adverse events in less than 10% of the study population, as a measure of safety	3 months
Primary	To assess the efficacy of EV-Pure™ and WJ-Pure™ compared to placebo, in patients with moderate to severe ARDS assoociated with COVID-19	Clinical data will be evaluated to determine if there were any significant changes in the COVID-19 symptoms in patients in the treated versus placebo groups. The following information will be collected to evaluate the effectiveness of the treatment at 4 weeks post- treatment: Discharged home on no supplemental oxygen; Discharged home on supplemental oxygen; Continued hospitalization on no oxygen; Continued hospitalization on oxygen but not in ICU; Continued hospitalization on oxygen in ICU (invasive and noninvasive ventilatory support); Death	3 Months
Secondary	Time to clinical improvement	The following information will be collected from the subjects during the follow-up visits or calls: Medical history review; Physical exam and vital signs; Assessment for delayed adverse reactions	3 months
Secondary	Overall Survival	Survival of the subjects in the 2 arms of the study	3 months
Secondary	COVID-19 polymerase chain reaction (PCR) test result as negative	COVID-19 polymerase chain reaction (PCR) test result as negative in the subjects in the 2 arms of the study	3 months